
Quarterly report 2025-Q3
added 11-12-2025
Adverum Biotechnologies Cash Flow 2011-2026 | ADVM
Annual Cash Flow Adverum Biotechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-92.5 M | -90.9 M | -108 M | -108 M | -79.3 M | -49.2 M | -54 M | -45.4 M | - | - | - | - | - | - |
Depreciation & Amortization |
3.65 M | 5.64 M | 6.53 M | 4.64 M | 4.16 M | 1.57 M | 1.75 M | 2.1 M | 1.6 M | 812 K | 162 K | 26 K | 1 K | - |
Accounts Payables |
1.61 M | 1.92 M | 2.24 M | 1.39 M | 2.81 M | 4.1 M | 1.71 M | 1.73 M | 1.47 M | 605 K | 951 K | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | 886 K | 449 K | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Adverum Biotechnologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -42.8 M | - | - | -23.2 M | - | - | -22.4 M | - | -89.6 M | -57.8 M | -28.9 M | - | -82 M | -56.2 M | -22.3 M | - | -57.1 M | -30.5 M | -13.6 M | - | -34.3 M | -24.8 M | -13.2 M | - | -41.2 M | -24.3 M | -13 M | - | -33.2 M | -23.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
- | - | 683 K | - | - | 997 K | - | - | 1.59 M | - | 4.82 M | 3.03 M | 1.42 M | - | 3.32 M | 2.36 M | 1.17 M | - | 1.2 M | 1.3 M | 599 K | - | 400 K | 400 K | 426 K | - | 400 K | 500 K | 459 K | - | 500 K | 600 K | 516 K | - | 400 K | 300 K | 320 K | - | 241 K | 147 K | 118 K | - | 49 K | 25 K | 9 K | - | 7 K | 7 K | - | - | - | - | - | - | - | - | - |
Accounts Payables |
12.5 M | 4.75 M | 1.82 M | 2.11 M | 1.97 M | 1.9 M | 2.17 M | 1.42 M | 2.86 M | 2.24 M | 846 K | 4.7 M | 3.24 M | 1.39 M | 2.52 M | 2.26 M | 2.06 M | 2.81 M | 2.81 M | 2.81 M | 2.81 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 1.71 M | 1.71 M | 1.71 M | 1.71 M | 1.73 M | 1.73 M | 1.73 M | 1.73 M | 1.47 M | 1.47 M | 1.47 M | 1.47 M | 605 K | 605 K | 605 K | 605 K | 951 K | 951 K | 951 K | 951 K | 769 K | 769 K | 769 K | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 886 K | 886 K | 886 K | 886 K | 449 K | 449 K | 449 K | 449 K | - | 8 K | 8 K | - | 8 K | 8 K | 8 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Adverum Biotechnologies, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | ||
|
AbbVie
ABBV
|
$ 232.08 | 3.29 % | $ 411 B | ||
|
AbCellera Biologics
ABCL
|
$ 3.61 | 0.56 % | $ 1.08 B | ||
|
Abeona Therapeutics
ABEO
|
$ 5.12 | -1.54 % | $ 109 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.66 | -0.85 % | $ 773 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 24.56 | -0.32 % | $ 4.07 B | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | ||
|
Achieve Life Sciences
ACHV
|
$ 4.56 | -3.59 % | $ 90.4 M | ||
|
AC Immune SA
ACIU
|
$ 2.93 | -1.01 % | $ 229 M | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | ||
|
Aclaris Therapeutics
ACRS
|
$ 2.87 | -8.31 % | $ 352 M | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | ||
|
Adagene
ADAG
|
$ 2.96 | -4.67 % | $ 167 M | ||
|
ADC Therapeutics SA
ADCT
|
$ 4.1 | -0.73 % | $ 105 M | ||
|
Adial Pharmaceuticals
ADIL
|
$ 2.53 | - | $ 16.4 M | ||
|
ADMA Biologics
ADMA
|
$ 15.57 | 2.57 % | $ 3.71 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 16.02 | -2.67 % | $ 2.43 B | ||
|
ADiTx Therapeutics
ADTX
|
$ 0.46 | -4.63 % | $ 6.06 K | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | ||
|
Agenus
AGEN
|
$ 3.33 | -0.89 % | $ 1.19 M | ||
|
Agios Pharmaceuticals
AGIO
|
$ 30.23 | 0.83 % | $ 1.75 B | ||
|
AIM ImmunoTech
AIM
|
$ 0.91 | -8.59 % | $ 43.8 M | ||
|
Akebia Therapeutics
AKBA
|
$ 1.31 | -0.76 % | $ 337 M | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 0.24 | -8.87 % | $ 5.73 B | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | ||
|
Aldeyra Therapeutics
ALDX
|
$ 5.46 | -0.73 % | $ 328 M | ||
|
Alector
ALEC
|
$ 2.43 | -5.08 % | $ 250 M | ||
|
Aligos Therapeutics
ALGS
|
$ 7.03 | -6.27 % | $ 452 M | ||
|
Alkermes plc
ALKS
|
$ 30.1 | -2.05 % | $ 4.96 B | ||
|
Allogene Therapeutics
ALLO
|
$ 2.78 | 1.83 % | $ 436 M | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 332.92 | 0.51 % | $ 43.6 B | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | ||
|
Altimmune
ALT
|
$ 4.31 | -3.36 % | $ 306 M | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | ||
|
ALX Oncology Holdings
ALXO
|
$ 2.11 | -10.21 % | $ 110 M | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | ||
|
Amgen
AMGN
|
$ 388.16 | 2.33 % | $ 209 B | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M |